Mechanisms for oxidative stress in diabetic cardiovascular disease.
暂无分享,去创建一个
[1] G. Aldini,et al. Design, Synthesis, and Evaluation of Carnosine Derivatives as Selective and Efficient Sequestering Agents of Cytotoxic Reactive Carbonyl Species , 2009, ChemMedChem.
[2] J. Baynes,et al. The Metal Chelators, Trientine and Citrate, Inhibit the Development of Cardiac Pathology in the Zucker Diabetic Rat , 2009, Experimental diabetes research.
[3] N. Borradaile,et al. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment , 2009, Aging cell.
[4] Sushil K. Jain,et al. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. , 2009, Antioxidants & redox signaling.
[5] H. Meštrić,et al. Chlorination of ammonia and aliphatic amines by Cl2: DFT study of medium and substituent effects , 2009 .
[6] S. Bornstein,et al. Prediabetic and diabetic in vivo modification of circulating low-density lipoprotein attenuates its stimulatory effect on adrenal aldosterone and cortisol secretion. , 2008, The Journal of endocrinology.
[7] R. Testa,et al. Glucose "peak" and glucose "spike": Impact on endothelial function and oxidative stress. , 2008, Diabetes research and clinical practice.
[8] N. Fukagawa,et al. Age‐related differences in insulin‐like growth factor‐1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells , 2008, Journal of cellular physiology.
[9] Ping Zhang,et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.
[10] E. Bourdon,et al. Oxidative stresses induced by glycoxidized human or bovine serum albumin on human monocytes. , 2008, Free radical biology & medicine.
[11] S. Pennathur,et al. Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage , 2008, Reviews in Endocrine and Metabolic Disorders.
[12] Shufeng Zhou,et al. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. , 2008, Archives of biochemistry and biophysics.
[13] A. Chait,et al. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies , 2008, The Lancet.
[14] R. Testa,et al. Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.
[15] M. Davies,et al. Mammalian heme peroxidases: from molecular mechanisms to health implications. , 2008, Antioxidants & redox signaling.
[16] P. Sil,et al. Protection of arsenic-induced testicular oxidative stress by arjunolic acid , 2008, Redox report : communications in free radical research.
[17] Coral Barbas,et al. Identification of oxidized proteins in rat plasma using avidin chromatography and tandem mass spectrometry , 2008, Proteomics.
[18] Md. Ehsanul Hoque Mazumder,et al. Pharmacological Evaluation of Bangladeshi Medicinal Plants for Antioxidant Activity , 2008 .
[19] J. Sowers,et al. Redox imbalance in diabetes. , 2007, Antioxidants & redox signaling.
[20] J. LeLorier,et al. Effect of ramipril on the incidence of diabetes. , 2007, The New England journal of medicine.
[21] H. Cai,et al. Attenuation of Angiotensin II Signaling Recouples eNOS and Inhibits Nonendothelial NOX Activity in Diabetic Mice , 2007, Diabetes.
[22] G. Moneta,et al. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes , 2007 .
[23] A. Cumaoğlu,et al. Effects of antioxidant stobadine on protein carbonylation, advanced oxidation protein products and reductive capacity of liver in streptozotocin‐diabetic rats: Role of oxidative/nitrosative stress , 2007, BioFactors.
[24] C. Block,et al. Mechanisms linking obesity with cardiovascular disease , 2006, Nature.
[25] S. Haffner,et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.
[26] M. Laakso,et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.
[27] W. März,et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. , 2006, The Journal of clinical endocrinology and metabolism.
[28] J. Heinecke,et al. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. , 2006, Current opinion in cardiology.
[29] U. Smith,et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.
[30] Simon J. Walker,et al. NADPH oxidases in cardiovascular health and disease. , 2006, Antioxidants & redox signaling.
[31] E. Lander,et al. Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.
[32] K. Griendling,et al. Serial Review : The Role of Oxidative Stress in Diabetes mellitus Serial Review , 2006 .
[33] R. Leibel,et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. , 2006, The Journal of clinical investigation.
[34] Nimesh Mody,et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes , 2005, Nature.
[35] H. Cai,et al. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Williamson,et al. Reactive Carbonyls and Polyunsaturated Fatty Acids Produce a Hydroxyl Radical-like Species , 2005, Journal of Biological Chemistry.
[37] A. Chait,et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. , 2004, Diabetes.
[38] A. Chait,et al. Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species* , 2004, Journal of Biological Chemistry.
[39] A. Chait,et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[40] Michael Kinter,et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.
[41] S. Matsumoto,et al. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. , 2004, Free radical biology & medicine.
[42] S. Hazen. Myeloperoxidase and plaque vulnerability. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[43] S. Hazen,et al. Inflammatory and oxidative markers in atherosclerosis: Relationship to outcome , 2004, Current atherosclerosis reports.
[44] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[45] S. Pennathur,et al. Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. , 2004, Frontiers in bioscience : a journal and virtual library.
[46] H. Hammes,et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat , 2004, Diabetologia.
[47] M. Brownlee,et al. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats , 2004, Diabetologia.
[48] M. Desai,et al. Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.
[49] E. Topol,et al. Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.
[50] S. Hazen,et al. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment , 2003, Current opinion in lipidology.
[51] S. Hazen,et al. Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways , 2003, Circulation.
[52] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[53] D. O'leary,et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. , 2003, The New England journal of medicine.
[54] S. Hazen,et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.
[55] J. Heinecke. Clinical trials of vitamin E in coronary artery disease: Is it time to reconsider the low-density lipoprotein oxidation hypothesis? , 2003, Current atherosclerosis reports.
[56] H. Hammes,et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy , 2003, Nature Medicine.
[57] E. Feldman. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. , 2003, The Journal of clinical investigation.
[58] R. Collins,et al. Heart Protection Study , 2003, The Lancet.
[59] J. Heinecke. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. , 2003, The American journal of cardiology.
[60] G. Gao,et al. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes , 2003, Diabetologia.
[61] Daniel Steinberg,et al. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime , 2002, Nature Medicine.
[62] Alan W. Stitt,et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.
[63] J. Heinecke. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. , 2002, Free radical biology & medicine.
[64] M. Steffes,et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.
[65] A. Schmidt,et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes , 2002, Ageing Research Reviews.
[66] T. Metz,et al. A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.
[67] R. Hotchkiss,et al. Myeloperoxidase produces nitrating oxidants in vivo , 2002 .
[68] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[69] R. Hotchkiss,et al. NADPH oxidase of neutrophils elevates o,o'-dityrosine cross-links in proteins and urine during inflammation. , 2001, Archives of biochemistry and biophysics.
[70] R. Stocker,et al. Oxidants and antioxidants in atherosclerosis , 2001, Current opinion in lipidology.
[71] J. Heinecke. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[72] W C Willett,et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.
[73] C. Gerhardinger,et al. Early cellular and molecular changes induced by diabetes in the retina , 2001, Diabetologia.
[74] A. Schmidt,et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.
[75] K. Litwak,et al. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. , 2001, The Journal of clinical investigation.
[76] V. Monnier,et al. Transition metals redox: reviving an old plot for diabetic vascular disease. , 2001, The Journal of clinical investigation.
[77] G. FitzGerald,et al. Effects of vitamin E on lipid peroxidation in healthy persons. , 2001, JAMA.
[78] Christopher K. Glass,et al. Atherosclerosis The Road Ahead , 2001, Cell.
[79] G. Shulman,et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver , 2001, Nature.
[80] R. Wiklund,et al. Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients , 2000 .
[81] S. Hazen,et al. Nitric Oxide Is a Physiological Substrate for Mammalian Peroxidases* , 2000, The Journal of Biological Chemistry.
[82] H. Utsumi,et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.
[83] I. G. Fantus,et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[84] M. Boaz,et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.
[85] F. Cipollone,et al. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. , 2000, Cardiovascular research.
[86] A. Jenkins,et al. Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.
[87] J. Baynes,et al. Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.
[88] D. Greene,et al. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. , 2000, European journal of pharmacology.
[89] Y. Kaneda,et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.
[90] S. Haffner. Coronary heart disease in patients with diabetes. , 2000, The New England journal of medicine.
[91] A. Morris,et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. , 2000, Hypertension.
[92] Matthew D. Davis,et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.
[93] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[94] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[95] S. Yusuf,et al. Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.
[96] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[97] F. Gries,et al. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[98] S. Pennathur,et al. Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease* , 1999, The Journal of Biological Chemistry.
[99] R. Ross. Atherosclerosis is an inflammatory disease , 1999 .
[100] S. Cuzzocrea,et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. , 1999, Science.
[101] S. Ihm,et al. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. , 1999, Metabolism: clinical and experimental.
[102] M. Hanefeld,et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. , 1999, Diabetes care.
[103] J. Heinecke. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[104] C van Ypersele de Strihou,et al. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.
[105] G. Davı̀,et al. In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus , 1999 .
[106] J. Baynes,et al. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.
[107] J. Holloszy,et al. Oxidized amino acids in the urine of aging rats: potential markers for assessing oxidative stress in vivo. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[108] G. Davı̀,et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. , 1999, Circulation.
[109] T. Miyata,et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.
[110] David M Nathan,et al. Some answers, more controversy, from UKPDS , 1998, The Lancet.
[111] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[112] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[113] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[114] K. Pritchard,et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[115] Barry Halliwell,et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils , 1998, Nature.
[116] G. King,et al. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus , 1997, Journal of Molecular Medicine.
[117] D. Nathan. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. , 1998, Lancet.
[118] J. Holloszy,et al. Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. , 1998, The American journal of physiology.
[119] R. Stocker,et al. α‐Tocopherol does not inhibit hypochlorite‐induced oxidation of apolipoprotein B‐100 of low‐density lipoprotein , 1997 .
[120] G. King,et al. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. , 1997, Kidney international. Supplement.
[121] T. Lyons,et al. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. , 1997, The Journal of clinical investigation.
[122] T. Lyons,et al. Carboxymethylethanolamine, a Biomarker of Phospholipid Modification during the Maillard Reaction in Vivo * , 1997, The Journal of Biological Chemistry.
[123] C. Kilo,et al. Cytosolic NADH/NAD+ , free radicals, and vascular dysfunction in early diabetes mellitus , 1997, Diabetologia.
[124] S. L. Hazen,et al. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.
[125] C van Ypersele de Strihou,et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. , 1997, Kidney international.
[126] K. Sharma,et al. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. , 1997, Seminars in nephrology.
[127] C. Semenkovich,et al. The Mystery of Diabetes and Atherosclerosis: Time for a New Plot , 1997, Diabetes.
[128] A. Jenkins,et al. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. , 1997, The Biochemical journal.
[129] F. Hsu,et al. Mass Spectrometric Quantification of Markers for Protein Oxidation by Tyrosyl Radical, Copper, and Hydroxyl Radical in Low Density Lipoprotein Isolated from Human Atherosclerotic Plaques* , 1997, The Journal of Biological Chemistry.
[130] S. L. Hazen,et al. Reactive Nitrogen Intermediates Promote Low Density Lipoprotein Oxidation in Human Atherosclerotic Intima* , 1997, The Journal of Biological Chemistry.
[131] F. Gries,et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. , 1997, Diabetes care.
[132] J. Heinecke. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine , 1997, BioFactors.
[133] David H. Williams,et al. Phosphorylation of SLP-76 by the ZAP-70 Protein-tyrosine Kinase Is Required for T-cell Receptor Function* , 1996, The Journal of Biological Chemistry.
[134] S. Bursell,et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. , 1996, Science.
[135] M. Matsumoto,et al. Rage: A Novel Cellular Receptor for Advanced Glycation End Products , 1996, Diabetes.
[136] S. Bursell,et al. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.
[137] T. Lyons,et al. The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.
[138] R. Schmidt,et al. Effect of Aminoguanidine on the Frequency of Neuroaxonal Dystrophy in the Superior Mesenteric Sympathetic Autonomic Ganglia of Rats With Streptozocin-Induced Diabetes , 1996, Diabetes.
[139] A. Jenkins,et al. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[140] A. Pfeiffer,et al. Diabetic microvascular complications and growth factors. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[141] R. Bucala,et al. Advanced glycosylation end products in diabetic renal and vascular disease. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[142] L. Packer,et al. alpha-Lipoic acid as a biological antioxidant. , 1995, Free radical biology & medicine.
[143] H. Tritschler,et al. Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy , 1995, Diabetes Care.
[144] T. Batchelder,et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. , 1995, Archives of ophthalmology.
[145] B. Margetts. United Kingdom prospective diabetes study , 1995, BMJ.
[146] L. Packer,et al. Alpha-lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. , 1995, Free radical biology & medicine.
[147] M. Brownlee,et al. Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.
[148] S. Grundy,et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[149] J. Heinecke,et al. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. , 1994, The Journal of biological chemistry.
[150] A. Chait,et al. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. , 1994, The Journal of clinical investigation.
[151] A. Daugherty,et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. , 1994, The Journal of clinical investigation.
[152] H. Ischiropoulos,et al. Oxidative chemistry of peroxynitrite. , 1994, Methods in enzymology.
[153] B. Halliwell,et al. Detection of hydroxyl radicals by aromatic hydroxylation. , 1994, Methods in enzymology.
[154] D. Steinberg,et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[155] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[156] B. Ames,et al. Oxidants, antioxidants, and the degenerative diseases of aging. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[157] R. Bucala,et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[158] J. Baynes,et al. Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. , 1993, The Journal of biological chemistry.
[159] T. Lyons,et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. , 1993, The Journal of clinical investigation.
[160] J. Nyengaard,et al. Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.
[161] T. Lyons,et al. Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging a , 1992, Annals of the New York Academy of Sciences.
[162] J. Baynes,et al. o‐Tyrosine and Dityrosine Concentrations in Oxidized Proteins and Lens Proteins with Age a , 1992, Annals of the New York Academy of Sciences.
[163] J. Goldstein,et al. Koch's postulates for cholesterol , 1992, Cell.
[164] V. Monnier,et al. Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM , 1992, Diabetes.
[165] H. Hammes,et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[166] J. Baynes,et al. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.
[167] D. Steinberg,et al. Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.
[168] S. Wolff,et al. Autoxidative Glycosylation and Possible Involvement of Peroxides and Free Radicals in LDL Modification by Glucose , 1990, Diabetes.
[169] J L Witztum,et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.
[170] R. Dean,et al. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.
[171] M. Haberland,et al. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.
[172] T. Carew,et al. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[173] A. Ooshima,et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[174] A. Cerami,et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.
[175] S. Young,et al. Probucol inhibits oxidative modification of low density lipoprotein. , 1986, The Journal of clinical investigation.
[176] A. Chait,et al. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. , 1984, The Journal of clinical investigation.
[177] D. Morel,et al. Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.
[178] J L Witztum,et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[179] S. Klebanoff. Oxygen metabolism and the toxic properties of phagocytes. , 1980, Annals of internal medicine.
[180] M. Brown,et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[181] R. Clark,et al. The neutrophil: Function and clinical disorders , 1978 .